Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):316-20.
From 1979 to 1985, 2435 patients thought to have had a transient ischaemic attack or minor ischaemic stroke were allocated at random to receive long term blind treatment with either aspirin 600 mg twice daily (n = 815), aspirin 300 mg once daily (806), or placebo (814). Treatment continued with about 85% compliance until September 1986 (mean four years). The odds of suffering one or more of four categories of event--namely, non-fatal myocardial infarction, non-fatal major stroke, vascular death, or non-vascular death--were 18% less in the two groups allocated to receive aspirin than in the group allocated to receive placebo (2p = 0.01). The more relevant but less frequent composite event of disabling stroke or vascular death was reduced by only 7%; this reduction was not significantly different from zero, but nor was it significantly different from a 25% reduction. There was no definite difference between responses to the 300 mg and 1200 mg daily doses, except that the lower dose was significantly less gastrotoxic.
1979年至1985年期间，2435名被认为曾发生短暂性脑缺血发作或轻度缺血性中风的患者被随机分配，接受长期盲法治疗，其中一组每日两次服用600毫克阿司匹林（n = 815），一组每日一次服用300毫克阿司匹林（806人），另一组服用安慰剂（814人）。治疗持续进行，依从率约为85%，直至1986年9月（平均四年）。在分配接受阿司匹林治疗的两组中，发生四类事件（即非致命性心肌梗死、非致命性严重中风、血管性死亡或非血管性死亡）中一种或多种事件的几率，比分配接受安慰剂治疗的组低18%（P = 0.01）。致残性中风或血管性死亡这一更相关但发生率较低的复合事件仅降低了7%；这一降低与零无显著差异，但与降低25%也无显著差异。除了较低剂量的胃肠道毒性显著较小外，每日300毫克和1200毫克剂量的反应之间没有明确差异。
